Occudo Quantitative Strategies LP purchased a new stake in shares of DaVita Inc. (NYSE:DVA - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,938 shares of the company's stock, valued at approximately $290,000.
Several other large investors also recently bought and sold shares of DVA. United Capital Financial Advisors LLC grew its stake in shares of DaVita by 2.6% in the fourth quarter. United Capital Financial Advisors LLC now owns 2,416 shares of the company's stock worth $361,000 after acquiring an additional 62 shares during the period. Freedom Investment Management Inc. grew its position in DaVita by 3.6% in the 4th quarter. Freedom Investment Management Inc. now owns 1,790 shares of the company's stock worth $268,000 after purchasing an additional 62 shares during the period. Exchange Traded Concepts LLC raised its stake in DaVita by 8.3% during the 4th quarter. Exchange Traded Concepts LLC now owns 891 shares of the company's stock valued at $133,000 after buying an additional 68 shares during the last quarter. Impact Partnership Wealth LLC lifted its holdings in shares of DaVita by 3.7% during the 4th quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company's stock valued at $290,000 after buying an additional 70 shares during the period. Finally, Nilsine Partners LLC boosted its stake in shares of DaVita by 0.8% in the 4th quarter. Nilsine Partners LLC now owns 11,160 shares of the company's stock worth $1,669,000 after buying an additional 92 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on the company. Cowen reissued a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a research report on Friday, February 21st. Barclays raised their price objective on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 18th. Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Finally, Truist Financial dropped their price target on shares of DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a research note on Monday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $164.50.
Check Out Our Latest Stock Analysis on DVA
DaVita Price Performance
Shares of DVA traded down $1.60 during mid-day trading on Thursday, reaching $139.26. The stock had a trading volume of 142,807 shares, compared to its average volume of 827,537. The business has a fifty day moving average of $145.76 and a 200 day moving average of $153.46. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The firm has a market cap of $10.51 billion, a price-to-earnings ratio of 12.97, a PEG ratio of 1.07 and a beta of 1.14. DaVita Inc. has a 12 month low of $131.44 and a 12 month high of $179.60.
DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.75 by $0.25. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The business had revenue of $3.22 billion during the quarter, compared to analyst estimates of $3.22 billion. During the same quarter in the prior year, the business posted $2.26 EPS. DaVita's revenue for the quarter was up 5.0% compared to the same quarter last year. Equities analysts predict that DaVita Inc. will post 10.76 EPS for the current year.
About DaVita
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
